Sarcoidosis

Immunology and Allergy Clinics of North America

Volumn 32, Issue 4, 2012, Pages 487-511

  Culver, Daniel A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Corticosteroids; EBUS TBNA; Granulomas; HLA; Infliximab; Sarcoidosis; Steroid sparing; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID;

BONE DISEASE; CAUSAL ATTRIBUTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; HEPATITIS; HISTORY; HUMAN; LUNG FUNCTION TEST; LUNG SARCOIDOSIS; LYMPHADENITIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; SPLEEN DISEASE; THERAPY DELAY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT;

HUMANS; SARCOIDOSIS;

EID: 84868011849     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2012.08.005     Document Type: Review

References (119)

1. Rybicki B.A., Major M., Popovich J., et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997, 145(3):234-241.
2. Cozier Y.C., Berman J.S., Palmer J.R., et al. Sarcoidosis in black women in the United States: data from the Black Women's Health Study. Chest 2011, 139(1):144-150.
3. McDonough C., Gray G.C. Risk factors for sarcoidosis hospitalization among U.S. Navy and Marine Corps personnel, 1981 to 1995. Mil Med 2000, 165(8):630-632.
4. Gentry J.T., Nitowsky H.M., Michael M. Studies on the epidemiology of sarcoidosis in the United States: the relationship to soil areas and to urban-rural residence. J Clin Invest 1955, 34(12):1839-1856.
5. Yamaguchi M., Hosoda Y., Sasaki R., et al. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis 1989, 6(2):138-146.
6. Reid J.D. Sarcoidosis in coroner's autopsies: a critical evaluation of diagnosis and prevalence from Cuyahoga County, Ohio. Sarcoidosis Vasc Diffuse Lung Dis 1998, 15(1):44-51.
7. Hosoda Y., Yamaguchi M., Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us?. Clin Chest Med 1997, 18(4):681-694.
8. Culver D.A., Thomassen M.J., Kavuru M.S. Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies. Cleve Clin J Med 2004, 71(2):88-90. 2 passim.
9. Ishige I., Usui Y., Takemura T., et al. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999, 354(9173):120-123.
10. Song Z., Marzilli L., Greenlee B.M., et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005, 201(5):755-767.
11. Oswald-Richter K.A., Culver D.A., Hawkins C., et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun 2009, 77(9):3740-3748.
12. Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med 2010, 31(4):380-389.
13. Sverrild A., Backer V., Kyvik K.O., et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008, 63(10):894-896.
14. Rybicki B.A., Iannuzzi M.C., Frederick M.M., et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001, 164(11):2085-2091.
15. McGrath D.S., Daniil Z., Foley P., et al. Epidemiology of familial sarcoidosis in the UK. Thorax 2000, 55(9):751-754.
16. Rossman M.D., Thompson B., Frederick M., et al. HLA-DRB1 1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003, 73(4):720-735.
17. Valentonyte R., Hampe J., Huse K., et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005, 37(4):357-364.
18. Wijnen P.A., Voorter C.E., Nelemans P.J., et al. Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression?. Hum Immunol 2011, 72(4):342-347.
19. Rybicki B.A., Walewski J.L., Maliarik M.J., et al. The BTNL2 gene and sarcoidosis susceptibility in African Americans and whites. Am J Hum Genet 2005, 77(3):491-499.
20. Li Y., Wollnik B., Pabst S., et al. BTNL2 gene variant and sarcoidosis. Thorax 2006, 61(3):273-274.
21. Spagnolo P., Sato H., Grutters J.C., et al. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens 2007, 70(3):219-227.
22. Hofmann S., Franke A., Fischer A., et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008, 40(9):1103-1106.
23. Li Y., Pabst S., Kubisch C., et al. First independent replication study confirms the strong genetic association of ANXA11 with sarcoidosis. Thorax 2010, 65(10):939-940.
24. Mrazek F., Stahelova A., Kriegova E., et al. Functional variant ANXA11 R230C: true marker of protection and candidate disease modifier in sarcoidosis. Genes Immun 2011, 12(6):490-494.
25. Franke A., Fischer A., Nothnagel M., et al. Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. Gastroenterology 2008, 135(4):1207-1215.
26. Fischer A., Schmid B., Ellinghaus D., et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. Am J Respir Crit Care Med 2012, [Epub ahead of print].
27. Hofmann S., Fischer A., Till A., et al. A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J 2011, 38(5):1127-1135.
28. Rybicki B.A., Levin A.M., McKeigue P., et al. A genome-wide admixture scan for ancestry-linked genes predisposing to sarcoidosis in African-Americans. Genes Immun 2011, 12(2):67-77.
29. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16(2):149-173.
30. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164(10 Pt 1):1885-1889.
31. Judson M.A., Thompson B.W., Rabin D.L., et al. The diagnostic pathway to sarcoidosis. Chest 2003, 123(2):406-412.
32. Highland K.B., Retalis P., Coppage L., et al. Is there an anatomic explanation for chest pain in patients with pulmonary sarcoidosis?. South Med J 1997, 90(9):911-914.
33. Lynch J.P., Ma Y.L., Koss M.N., et al. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007, 28(1):53-74.
34. Sharma O.P., Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988, 94(2):343-346.
35. Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001, 120(3):881-886.
36. Wilsher M.L., Fergusson W., Milne D., et al. Exhaled nitric oxide in sarcoidosis. Thorax 2005, 60(11):967-970.
37. Bein M.E., Putman C.E., McLoud T.C., et al. A reevaluation of intrathoracic lymphadenopathy in sarcoidosis. AJR Am J Roentgenol 1978, 131(3):409-415.
38. Nunes H., Uzunhan Y., Gille T., et al. Imaging of sarcoidosis of the airways and lung parenchyma with correlation with lung function. Eur Respir J 2012, 40(3):750-765.
39. Rosen Y., Vuletin J.C., Pertschuk L.P., et al. Sarcoidosis: from the pathologist's vantage point. Pathol Annu 1979, 14(Pt 1):405-439.
40. Teirstein A.S., Machac J., Almeida O., et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007, 132(6):1949-1953.
41. Teirstein A.S., Judson M.A., Baughman R.P., et al. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22(2):139-146.
42. Baughman R.P., Culver D.A., Judson M.A. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011, 183(5):573-581.
43. Tremblay A., Stather D.R., Maceachern P., et al. A randomized controlled trial of standard vs endobronchial ultrasonography-guided transbronchial needle aspiration in patients with suspected sarcoidosis. Chest 2009, 136(2):340-346.
44. Oki M., Saka H., Kitagawa C., et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration is useful for diagnosing sarcoidosis. Respirology 2007, 12(6):863-868.
45. Garwood S., Judson M.A., Silvestri G., et al. Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis. Chest 2007, 132(4):1298-1304.
46. Navani N., Booth H.L., Kocjan G., et al. Combination of endobronchial ultrasound-guided transbronchial needle aspiration with standard bronchoscopic techniques for the diagnosis of stage I and stage II pulmonary sarcoidosis. Respirology 2011, 16(3):467-472.
47. Navani N., Lawrence D.R., Kolvekar S., et al. EBUS-TBNA prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial. Am J Respir Crit Care Med 2012, 186(3):255-260.
48. Gilman M.J., Wang K.P. Transbronchial lung biopsy in sarcoidosis. An approach to determine the optimal number of biopsies. Am Rev Respir Dis 1980, 122(5):721-724.
49. Koonitz C.H., Joyner L.R., Nelson R.A. Transbronchial lung biopsy via the fiberoptic bronchoscope in sarcoidosis. Ann Intern Med 1976, 85(1):64-66.
50. Nagai S., Izumi T. Bronchoalveolar lavage. Still useful in diagnosing sarcoidosis?. Clin Chest Med 1997, 18(4):787-797.
51. Meyer K.C., Raghu G., Baughman R.P., et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012, 185(9):1004-1014.
52. Kaiser P.K., Lowder C.Y., Sullivan P., et al. Chest computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol 2002, 133(4):499-505.
53. Judson M.A. The diagnosis of sarcoidosis. Clin Chest Med 2008, 29(3):415-427. viii.
54. Wakefield D., Zierhut M. Controversy: ocular sarcoidosis. Ocul Immunol Inflamm 2010, 18(1):5-9.
55. Kandolin R., Lehtonen J., Graner M., et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011, 270(5):461-468.
56. Muller-Quernheim J., Gaede K.I., Fireman E., et al. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006, 27(6):1190-1195.
57. Fireman E., Haimsky E., Noiderfer M., et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(2):144-148.
58. Ribeiro M., Fritscher L.G., Al-Musaed A.M., et al. Search for chronic beryllium disease among sarcoidosis patients in Ontario, Canada. Lung 2011, 189(3):233-241.
59. Morimoto Y., Routes J.M. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep 2005, 5(5):370-375.
60. Brincker H. Granulomatous lesions of unknown significance: the GLUS syndrome. Sarcoidosis and other granulomatous disorders 1994, 69-76. Marcel Dekker, New York. D. James (Ed.).
61. Rose C.D., Martin T.M., Wouters C.H. Blau syndrome revisited. Curr Opin Rheumatol 2011, 23(5):411-418.
62. Judson M.A., Baughman R.P., Thompson B.W., et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(3):204-211.
63. Hamzeh N.Y., Wamboldt F.S., Weinberger H.D. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012, 141(1):154-162.
64. Patel M.R., Cawley P.J., Heitner J.F., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009, 120(20):1969-1977.
65. Studdy P.R., Bird R., Neville E., et al. Biochemical findings in sarcoidosis. J Clin Pathol 1980, 33(6):528-533.
66. Tomita H., Ina Y., Sugiura Y., et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997, 156(1):255-259.
67. Rothkrantz-Kos S., van Dieijen-Visser M.P., Mulder P.G., et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003, 49(9):1510-1517.
68. Baughman R.P., Ploysongsang Y., Roberts R.D., et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis 1983, 128(4):631-633.
69. Gronhagen-Riska C., Selroos O., Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis 1980, 61(2):113-122.
70. Ziegenhagen M.W., Rothe M.E., Schlaak M., et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003, 21(3):407-413.
71. Scadding J.G. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961, 5261:1165-1172.
72. Baughman R.P., Costabel U., du Bois R.M. Treatment of sarcoidosis. Clin Chest Med 2008, 29(3):533-548. ix-x.
73. Lazar C.A., Culver D.A. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010, 31(4):501-518.
74. Baughman R.P., Shipley R., Desai S., et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009, 136(2):526-535.
75. Judson M.A., Gilbert G.E., Rodgers J.K., et al. The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis. Respirology 2008, 13(1):97-102.
76. Barros W.G., Neder J.A., Pereira C.A., et al. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respiration 2004, 71(4):367-373.
77. Baughman R.P., Drent M., Kavuru M., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174(7):795-802.
78. Lynch J.P., Kazerooni E.A., Gay S.E. Pulmonary sarcoidosis. Clin Chest Med 1997, 18(4):755-785.
79. Judson M.A. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007, 28(1):83-101.
80. Sharma O.P. Cutaneous sarcoidosis: clinical features and management. Chest 1972, 61(4):320-325.
81. Stern B.J., Krumholz A., Johns C., et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985, 42(9):909-917.
82. Lower E.E., Broderick J.P., Brott T.G., et al. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997, 157(16):1864-1868.
83. Tavee J., Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011, 15(3):201-206.
84. Dumas J.L., Valeyre D., Chapelon-Abric C., et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology 2000, 214(2):411-420.
85. Zajicek J.P., Scolding N.J., Foster O., et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999, 92(2):103-117.
86. Deng J.C., Baughman R.P., Lynch J.P. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med 2002, 23(6):513-527.
87. Tadamura E., Yamamuro M., Kubo S., et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 2005, 185(1):110-115.
88. Yamagishi H., Shirai N., Takagi M., et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003, 44(7):1030-1036.
89. Isiguzo M., Brunken R., Tchou P., et al. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28(1):50-55.
90. Uemura A., Morimoto S., Hiramitsu S., et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999, 138(2 Pt 1):299-302.
91. Vatti R., Sharma O.P. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis 1997, 14(1):73-76.
92. Kataria Y.P., Whitcomb M.E. Splenomegaly in sarcoidosis. Arch Intern Med 1980, 140(1):35-37.
93. James D.G., Neville E., Siltzbach L.E. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976, 278:321-334.
94. Panselinas E., Halstead L., Schlosser R.J., et al. Clinical manifestations, radiographic findings, treatment options, and outcome in sarcoidosis patients with upper respiratory tract involvement. South Med J 2010, 103(9):870-875.
95. Gribbin J., Hubbard R.B., Le Jeune I., et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006, 61(11):980-985.
96. Swigris J.J., Olson A.L., Huie T.J., et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011, 183(11):1524-1530.
97. Sekiguchi M., Yazaki Y., Isobe M., et al. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996, 10(5):495-510.
98. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N Engl J Med 2007, 357(21):2153-2165.
99. Siltzbach L.E., James D.G., Neville E., et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974, 57(6):847-852.
100. Baughman R.P., Judson M.A., Teirstein A., et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006, 99(5):307-315.
101. Hunninghake G.W., Gilbert S., Pueringer R., et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994, 149(4 Pt 1):893-898.
102. Grunewald J., Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009, 179(4):307-312.
103. Gottlieb J.E., Israel H.L., Steiner R.M., et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997, 111(3):623-631.
104. Pietinalho A., Tukiainen P., Haahtela T., et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002, 121(1):24-31.
105. Culver D.A. Pro: the treatment of the granulomatous response is beneficial in acute sarcoidosis. Respir Med 2010, 104(12):1775-1777.
106. Gibson G.J., Prescott R.J., Muers M.F., et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996, 51(3):238-247.
107. Schutt A.C., Bullington W.M., Judson M.A. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010, 104(5):717-723.
108. Sahoo D.H., Bandyopadhyay D., Xu M., et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011, 38(5):1145-1150.
109. Androdias G., Maillet D., Marignier R., et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011, 76(13):1168-1172.
110. Bhat P., Cervantes-Castaneda R.A., Doctor P.P., et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009, 17(3):185-190.
111. Judson M.A., Baughman R.P., Costabel U., et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008, 31(6):1189-1196.
112. Carter J.D., Valeriano J., Vasey F.B., et al. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004, 117(4):277-279.
113. Doty J.D., Mazur J.E., Judson M.A. Treatment of sarcoidosis with infliximab. Chest 2005, 127(3):1064-1071.
114. Moravan M., Segal B.M. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009, 72(4):337-340.
115. Saleh S., Ghodsian S., Yakimova V., et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006, 100(11):2053-2059.
116. Sodhi M., Pearson K., White E.S., et al. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009, 103(2):268-273.
117. Erckens R.J., Mostard R.L., Wijnen P.A., et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012, 250(5):713-720.
118. Kamphuis L.S., Lam-Tse W.K., Dik W.A., et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011, 184(10):1214-1216.
119. Milman N., Graudal N., Loft A., et al. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2011, 10.1111/j.1752-699X.2011.00276.x.